10
Dec
2024

Chongqing Zhifei Biological Products Co., Ltd.

Exhibitor at CPHI Middle East 2024 stand 3.A14
About Us

Chongqing Zhifei Biological Products Co., Ltd. is the largest listed vaccine company in China，which has its presence in biological product industry in 2002.The Company achieved an operating income of RMB38.3 billion In  2022 with the support of its nearly 7000 employees.As a high-tech biological enterprise integrating the R&D, production, marketing, distribution as well as import & export, Zhifei mainly engages in the production of vaccines for human use. Our research channels cover many indications extensively: like COVID-19, tuberculosis, meningitis, etc.

Read more Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • CN
  • 2015
    On CPHI since
  • 5000+
    Employees
Company types
Manufacturer/Innovator
View company profile
Contact info
Show contact info Hide contact info
Event information
CPHI Middle East 2024
  • 10 Dec 2024 - 12 Dec 2024
  • Riyadh Front Exhibition & Convention Center Riyadh, Saudi Arabia
  • Visit us at stand 3.A14

Products Featured at CPHI Middle East 2024

  • Recombinant Mycobacterium Tuberculosis Fusion Protein

    Product Recombinant Mycobacterium Tuberculosis Fusion Protein

    C-TST is a new diagnose method to detect Mtb infectionfor,which uses antigen-specific (ESAT6 & CFP10) immune response, same with the principle of action used in IGRAs.(1）Suitable for Large Scale LTBI Screening； 
    (2）Non Cross-React with BCG Vaccine; 
    (3）WHO Guideline Recommended;  q...
  • semaglutide

    Product semaglutide

    we can supply the semaglutide API with a good price and good quality,we are also open for the cooperation model.
  • Meningococcal Polysaccharide Vaccine

    Product Meningococcal Polysaccharide Vaccine

    Chongqing zhifei biological products co., ltd offers a wide range of products which includes meningococcal polysaccharide vaccine. Function and use: it can be used to prevent epidemic cerebrospinal meningitis caused by meningococcus group a, c, y, and w135 infection. Contact us for more information.
  • Group A, C Meningococcal Polysaccharide-Conjugate Vaccine

    Product Group A, C Meningococcal Polysaccharide-Conjugate Vaccine

    MeningACon is the first approved product in China,more than 36 million doses has been used.
  • 23-valent Pneumococcal PolysaccharideVaccine

    Product 23-valent Pneumococcal PolysaccharideVaccine

    Covers a wider range of pneumococcal serotypesMore economical for low-and middle-income countries
    Patented process
    Great immunogenicity and safety
    Prefilled Syringe